Following news that Cambridge Respiratory Innovations has teamed with several NHS trusts to supply N-Tidal (capnography) devices in order to help doctors identify when to ventilate COVID-19 patients;

Aliyah Farouk, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view:

“The accelerated production of N-Tidal devices by Cambridge Respiratory Innovations to combat the COVID-19 outbreak could result in a major order globally, making the company a crucial player in the capnography market. The global capnographs market, set to reach $661m by 2028 and growing at a compound annual growth rate (CAGR) of 2.8%, is led by Medtronic.

“Cambridge Respiratory Innovations currently has 200 capnographs that it can deploy to NHS trusts but anticipates the production of tens of thousands of the device in the near future. The handheld device allows coronavirus patients to monitor their breathing without the need for supervision. With a shortage of ventilators, clinicians can prioritize their use based on firm data from the device.

“The company also plans to seek regulatory approval for the incorporation of artificial intelligence in the device, forecasting whether a patient will need a ventilator in a given time period. This eliminates the necessity of clinicians taking numerous observations when assessing coronavirus patients, especially during the management of busy wards with numerous critically ill patients.

“The capnographs market is transitioning towards patient monitoring systems as a whole. Cambridge Respiratory Innovations capitalizing on this need will set them apart from competitors as they enter a highly competitive market.”